Mesoporous zinc oxide-based drug delivery system offers an antifungal and immunoregulatory strategy for treating keratitis
Journal of Controlled Release · 2024-04 · 368 · 483-497
DOI: 10.1016/j.jconrel.2024.03.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2024-04. Verfasst von Lingwen Gu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao 266003, PR China. Hauptthemen laut MEDLINE: Zinc Oxide, Aspergillosis, Keratitis, Eye Infections, Fungal. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 71 Literaturangaben. Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Taishan Scholar Foundation of Shandong Province.
Abstract (Originalsprache)
Fungal keratitis is a refractory eye disease that is prone to causing blindness. Fungal virulence and inflammatory responses are two major factors that accelerate the course of fungal keratitis. However, the current antifungal drugs used for treatment usually possess transient residence time on the ocular surface and low bioavailability deficiencies, which limit their therapeutic efficacy. In this work, natamycin (NATA)-loaded mesoporous zinc oxide (Meso-ZnO) was synthesized for treating Aspergillus fumigatus keratitis with excellent drug-loading and sustained drug release capacities. In addition to being a carrier for drug delivery, Meso-ZnO could restrict fungal growth in a concentration-dependent manner, and the transcriptome analysis of fungal hyphae indicated that it inhibited the mycotoxin biosynthesis, oxidoreductase activity and fungal cell wall formation. Meso-ZnO also promoted cell migration and exhibited anti-inflammatory role during fungal infection by promoting the activation of autophagy. In mouse models of fungal keratitis, Meso-ZnO/NATA greatly reduced corneal fungal survival, alleviated tissue inflammatory damage, and reduced neutrophils accumulation and cytokines expression. This study suggests that Meso-ZnO/NATA can be a novel and effective treatment strategy for fungal keratitis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao 266003, PR China.
- School of Science, Qingdao University of Technology, Qingdao 266520, PR China.
- State Key Laboratory of Bio-fibers and Eco-textiles, Institute of Marine Biobased Materials, College of Materials Science and Engineering, Qingdao University, Qingdao 266071, PR China. Electronic address: lidaohao@qdu.e…
- Department of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao 266003, PR China. Electronic address: zhaoguiqiu_good@126.com.
- Department of Ophthalmology, The Affiliated Hospital of Qingdao University, Qingdao 266003, PR China. Electronic address: yankelicui@126.com.
Förderung
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
- Taishan Scholar Foundation of Shandong Province
Zitieren
APA
Gu, L., Lin, J., Wang, Q., Meng, F., Niu, G., Lin, H., Chi, M., Feng, Z., Zheng, H., Li, D., Zhao, G., & Li, C. (2024). Mesoporous zinc oxide-based drug delivery system offers an antifungal and immunoregulatory strategy for treating keratitis. Journal of Controlled Release, 368, 483-497. https://doi.org/10.1016/j.jconrel.2024.03.006
Vancouver
Gu L, Lin J, Wang Q, Meng F, Niu G, Lin H, et al. Mesoporous zinc oxide-based drug delivery system offers an antifungal and immunoregulatory strategy for treating keratitis. Journal of Controlled Release. 2024;368:483-497. doi:10.1016/j.jconrel.2024.03.006
BibTeX
@article{Gu2024,
author = {Gu, Lingwen and Lin, Jing and Wang, Qian and Meng, Fanyue and Niu, Geng and Lin, Hao and Chi, Menghui and Feng, Zhuhui and Zheng, Hengrui and Li, Daohao and Zhao, Guiqiu and Li, Cui},
title = {Mesoporous zinc oxide-based drug delivery system offers an antifungal and immunoregulatory strategy for treating keratitis},
journal = {Journal of Controlled Release},
year = {2024},
volume = {368},
pages = {483--497},
doi = {10.1016/j.jconrel.2024.03.006}
}
EUVIMED